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Background: There is limited data on complications associated with the use of
coronary embolic protection devices (EPDs).
Methods: We queried the Manufacturer and User Facility Device Experience database
between November 2010 and November 2020 for reports on coronary EPDs: Spider
FX (Medtronic, Minneapolis, MN) and Filterwire EZ (Boston Scientific, Natick, MA).
Results: We retrieved 119 reports on coronary EPD failure (Spider FX n = 33 and
Filterwire EZ n = 86), most of which (78.2%) occurred during saphenous vein graft
interventions. The most common failure mode was inability to retrieve the EPD
(49.6%), with the filter trapped against stent struts in 76.2% of the cases. Other
device complications included filter fracture (28.6%), failure to cross (7.6%), failure to
deploy (7.6%), and failure to recapture the filter (3.4%). Filter fracture (54.5
vs. 29.1%) and failure to recapture (9.1 vs. 2.1%) were more commonly reported,
while failure to deploy the filter (0 vs. 10.5%) was less commonly reported with the
Spider-FX.
Conclusions: The most common modes of failure of coronary EPDs are the failure of
retrieval (49.6%), followed by the filter fracture (28.6%). When using EPDs, careful
attention to the technique is essential to avoid failures and subsequent complications.
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1 | INTRODUCTION
Distal embolization is a potential risk of percutaneous coronary
intervention (PCI) that can lead to slow or no-reflow and acute vessel
closure, potentially leading to acute myocardial infarction.1,2 Emboli-
zation can occur at the time of lesion crossing, balloon inflation, or
stent deployment. Distal embolization is most pronounced in lesions
with a high plaque or thrombus burden, such as ST-segment elevation
acute myocardial infarction (STEMI) culprit lesions and saphenous vein
graft (SVG) lesions.3
Embolic protection devices (EPDs) can prevent or reduce the
extent of distal embolization of debris or thrombus, potentially reducing
adverse clinical outcomes. Randomized trials have shown beneficial effects
of EPDs on SVG interventions.3 EPDs have demonstrated no significant
benefit when routinely used in STEMI,4,5 although some reports suggest
benefit, for example, in patients with attenuated plaque.6,7 Currently,
EPDs are primarily used in SVG PCI.8 Data on the complications of coro-
nary EPDs are limited.9 Therefore, we examined the reports of coronary
EPDs failure reported to the Food and Drug Administration (FDA) Manu-
facturer and User Facility Device Experience (MAUDE) registry.
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TABLE 1 Reports of the Spider FX and Filterwire EZ device failure in the MAUDE registry
Overall (n = 119) SPIDER-FX (n = 33) FILTERWIRE-EZ (n = 86) p-value
Coronary location
Saphenous vein graft, n (%) 93 (78.2) 24 (72.2) 69 (80.2) .37
Native, n (%) 14 (11.8) 6 (18.2) 8 (9.3) .40
RCA, n (%) 9 (7.6) 5 (15.2) 4 (4.7) .05
LAD, n (%) 3 (2.5) 1 (3) 2 (2.3) .82
LCX, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
OM, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
Unknown, n (%) 12 (10) 3 (9.1) 9 (10.5) .82
Modes of failure
Failure of retrieval, n (%) 59 (49.6) 19 (57.6) 40 (46.5) .28
Trapped against stent struts (total n = 59) (%) 45 (76.2) 8 (42.1) 20 (50.0) .57
Filter fracture, n (%) 34 (28.6) 18 (54.5) 25 (29.1) .01
Failure of crossing, n (%) 13 (7.6) 2 (6.1) 11 (12.8) .29
Failure of deployment, n (%) 9 (7.6) 0 (0) 9 (10.5) .05
Failure of recapturing, n (%) 4 (3.4) 3 (9.1) 1 (1.2) .03
Management
Successful catheter-based retrieval, n (%) 67 (56.3) 8 (24.2) 59 (68.6) <.001
Snare, n (%) 12 (10.1) 5 (15.2) 7 (8.1) .25
Rotational atherectomy to dislodge trapped filter, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
Guide extension catheter, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
Left inside patient, n (%) 38 (31.9) 18 (54.5) 20 (23.3) <.001
Filter jailed with a stent, (total n = 38) (%) 20 (52.6) 9 (50.0) 11 (55.0) .75
Surgical retrieval, n (%) 13 (10.9) 7 (21.2) 6 (7) .02
Complications
Stent deformation during retrieval, n (%) 34 (28.6) 4 (3.4) 30 (34.9) .01
No reflow, n (%) 7 (5.9) 3 (9.1) 4 (4.7) .35
Slow flow, n (%) 11 (9.2) 5 (15.2) 6 (7.1) .17
Acute stent thrombosis, n (%) 1 (0.8) 1 (3) 0 (0) .10
Coronary perforation, n (%) 2 (1.7) 0 (0) 2 (2.3) .37
Coronary artery dissection, n (%) 3 (2.5) 1 (3) 2 (2.3) .82
Hemodynamic collapse, n (%) 2 (1.7) 2 (6.1) 0 (0) .02
Respiratory arrest, n (%) 2 (1.7) 1 (3) 1 (1.2) .47
Embolized 13 (10.9) 5 (15.2) 8 (9.3) .60
Microthrombi embolization, n (%) 4 (3.4) 1 (20) 3 (37.5) .50
Femoral embolization, n (%) 2 (1.7) 1 (20) 1 (12.5) .71
Abdominal embolization, n (%) 1 (0.8) 1 (20) 0 (0) .18
Iliac embolization, n (%) 1 (0.8) 0 (0) 1 (12.5) .41
Brachial embolization, n (%) 1 (0.8) 1 (20) 0 (0) .18
Periprocedural MI, n (%) 10 (8.4) 2 (6.1) 8 (9.3) .56
Stroke, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
Death, n (%) 1 (0.8) 0 (0) 1 (1.2) .53
Outcome
Successful intervention completed, n (%) 103 (86.6) 27 (81.8) 76 (88.4) .34
Abbreviations: LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; OM, obtuse marginal artery; SVG, saphenous
vein grafts.
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2 | MATERIALS AND METHODS
The FDA's MAUDE database is an online database of adverse events
caused by an approved medical device. Reporting to the MAUDE
database is either mandatory (for manufacturers and device user
facilities) or voluntary (for healthcare professionals, patients, and
consumers). We searched the database from November 2010
to November 2020 for reports on coronary EPDs: Spider FX
(Medtronic, MN) and Filterwire EZ (Boston Scientific, MA). The
Spider FX device was the most recently approved in 2011. The
Guardwire (Medtronic, Minneapolis, MN) and Proxis devices,
although FDA approved, were omitted because they are not cur-
rently commercially available in the US.
The database was last accessed on December 15, 2020, by
two independent reviewers (RM and MM). The MAUDE data-
base is publicly available and de-identified; therefore, no institu-
tional review board approval was required for this study. We
compared the baseline characteristics and outcomes between
the Spider-FX and Filterwire-EZ. We also compared outcomes in
patients who had EPDs used in SVGs versus in native coronary
disease.
2.1 | Outcomes and statistical analysis
The primary outcome of this study was the mechanisms of
failure of coronary EPDs. Secondary outcomes included clinical
consequences of device failure. Failure of retrieval of the EPD
was defined as the failure to extract the filter intact from the
vessel. Failure of recapture was defined as the inability to with-
draw the filter in the retrieval catheter. Categorical variables
were described as numbers and percentages. They were ana-
lyzed using Pearson's chi-square or Fisher's exact tests. A value
of p < .05 was considered significant, and p-values are two-
sided where possible. All statistical calculations were performed
with IBM SPSS Statistics for Mac, Version 26.0. Armonk, NY:
IBM Corp (2020).
2.2 | Results
A total of 677 reports were found during the study period. After exclud-
ing non-coronary (n = 455) and non-identifiable lesions (n = 113), our
final cohort included 119 reports related to EPD failure during PCI. Of
those, 33 reports were related to the use of the Spider FX (27.7%) and
86 to the Filterwire EZ (72.3%) (Figure S1). Most reports were during
SVG PCI (78.2%), while native coronary artery PCI was 11.8%. We could
not identify the target vessel in 10% of cases (Table 1).
2.3 | Mechanisms of failure and clinical outcomes
The most common failure mode was failure to retrieve the EPD
(49.6%), with the filter trapped against stent struts in 76.2% of
these cases. Other EPD complications included filter fracture
(28.6%), failure to cross (7.6%), failure to deploy (7.6%), and fail-
ure to recapture the filter (3.4%). There was no difference in the
incidence of failure of retrieval or crossing between the two fil-
ters. Spider-FX had higher reported incidence of filter fracture
(54.5% vs. 29.1%, p = .01) and failure to recapture (9.1 vs. 2.1%,
p = .03), but lower reported incidence of filter deployment fail-
ure (0 vs. 10.5%, p = .05) compared with the Filterwire-EZ
(Figure 1).
Management of entrapment was with catheter-based retrieval in
57.1% of the cases, while surgical retrieval was needed in 10.9% of
the reports. Successful catheter-based retrieval was reported in
66.3% of the Filterwire-EZ reports, and 34.4% of the Spider FX
reports. Surgical intervention was reported in 21% of the Spider-FX
cases and 7% of the Filterwire-EZ cases. The device was left in place
in 31.9% of the cases, and jailed by a stent in 52.6% of them. The Spi-
der FX was left in place in 54.5% of the reports compared with 23.3%
for the Filterwire-EZ.
Stent deformation occurred in 28.6% of the reports, with a higher
incidence with the Filterwire-EZ (34.9 vs. 3.4%, p = .01). Device
embolization occurred in 10.9% of cases with no difference between
both devices. The rates of slow flow and no-reflow were 9.2 and
F IGURE 1 Modes of failures of coronary
embolic protection devices as reported to the
MAUDE registry. MAUDE, Manufacturer and User
Facility Device Experience
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5.9%, respectively. Coronary perforation occurred in 1.7% of cases,
while coronary dissection occurred in 2.5% of cases. The rates of
death, stroke, and periprocedural MI were 0.8, 0.8, and 8.4%.
2.4 | Vein grafts versus native coronary disease
Coronary EPDs were primarily used in SVGs. Native artery interven-
tions were more likely to be associated with failure to recapture the
filter compared to SVG interventions (14.3 vs. 1.1%, p < .001). There
was no difference in the incidence of retrieval failure, filter fracture,
failure of crossing, or failure of deployment between SVG and native
artery interventions. There was no difference in clinical outcomes
between the two groups (Table 2).
3 | DISCUSSION
Our study is the first to report the modes of failure of coronary EPDs
over a decade of use in the United States. The main findings of our
TABLE 2 Subgroup analysis of clinical complication of embolic protection devices in native coronary artery versus vein graft interventions in
the MAUDE registry
Overall (n = 107) Native coronary arteries (n = 14) Vein grafts (n = 93) p-value
Mode of failure
Failure of retrieval, n (%) 53 (49.5) 3 (21.4) 50 (53.8) .24
Trapped against stent struts (total n = 59) (%) 45 (42.1) 5 (35.7) 40 (43.0) .60
Filter fracture, n (%) 40 (37.4) 5 (35.7) 35 (37.6) .89
Failure of crossing, n (%) 12 (11.2) 1 (7.1) 11 (11.8) .60
Failure of deployment, n (%) 7 (6.5) 0 (0) 7 (7.5) .28
Failure of recapturing, n (%) 3 (2.9) 2 (14.3) 1 (1.1) <.001
Management
Successful catheter-based retrieval, n (%) 60 (56.1) 8 (57.1) 52 (55.9) .93
Snare, n (%) 12 (11.2) 0 (0) 12 (12.9) .15
Rotational atherectomy to dislodge trapped filter, n (%) 1 (0.9) 1(7.1) 0 (0) .01
Guide extension catheter, n (%) 1 (0.9) 1 (7.1) 0 (0) .01
Left inside patient, n (%) 35 (32.7) 4 (28.6) 31 (33.3) .72
Filter jailed with a stent, (total n = 35) (%) 20 (52.6) 2 (50.0) 17 (54.8) .71
Surgical retrieval, n (%) 11 (10.3) 2 (14.3) 9 (9.7) .59
Complications
Stent deformation during retrieval, n (%) 33 (30.8) 4 (28.6) 29 (31.2) .84
No reflow, n (%) 7 (6.5) 0 (0) 7 (7.5) .28
Slow flow, n (%) 11 (10.4) 0 (0) 11 (12) .17
Acute stent thrombosis, n (%) 1 (0.9) 1 (7.1) 0 (0) .10
Coronary perforation, n (%) 2 (1.9) 0 (0) 2 (2.2) .58
Coronary artery dissection, n (%) 3 (2.8) 1 (7.1) 2 (2.2) .29
Hemodynamic collapse, n (%) 2 (1.9) 0 (0) 2 (2.2) .58
Respiratory arrest, n (%) 2 (1.9) 1 (7.1) 1 (1.1) .11
Embolized 12 (11.2) 4 (28.6) 8 (8.6) .02
Microthrombi embolization, n (%) 4 (30.8) 1 (25) 3 (37.5) .71
Femoral embolization, n (%) 2 (15.4) 1 (25) 1 (12.5) .77
Abdominal embolization, n (%) 1 (7.7) 0 (0) 1 (12.5) .71
Iliac embolization, n (%) 1 (7.7) 0 (0) 1 (12.5) .71
Brachial embolization, n (%) 1 (7.7) 0 (0) 1 (12.5) .71
Periprocedural MI, n (%) 4 (30.8) 1 (25) 3 (37.5) .71
Stroke, n (%) 0 (0) 0 (0) 0 (0) *
Death, n (%) 1 (0.9) 0 (0) 1 (1.1) .69
Outcome
Successful intervention completed, n (%) 93 (86.9) 12 (85.7) 81 (87.1) .88
Abbreviation: MI, myocardial infarction.
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study can be summarized as follows: (1) coronary EPDs were primarily
utilized in SVG PCI (78%) but are also sometimes used in native artery
interventions; (2) the most common complication of coronary EPD
use was retrieval failure (49%) followed by filter fracture (28.6%),
which was in most cases managed by catheter-based retrieval or leav-
ing the filter in place, with emergency surgery needed in 10.9% of the
cases.
SVG PCI is associated with a high risk of MACE, primarily due to
the risk of distal embolization. Although PCI of the corresponding
native coronary is preferred to SVG PCI if feasible,10 SVG PCI is still
commonly performed. The SAFER trial demonstrated a significant
benefit of EPD use in SVG PCI and formed the basis of current prac-
tice. Using an EPD in SVG PCI is recommended as class I in the US
PCI guidelines. In contrast, it was recently downgraded to IIA in the
European PCI guidelines based on data from observational stud-
ies.11,12 The use of EPDs during SVG PCI has been shown to reduce
the risk of distal embolization and MACE.8 However, multiple studies
have shown that EPD use during SVG PCI has been declining.11,12
The decline in their use might indirectly lead to limited experience and
higher complication rates.
EPDs carry a risk of complications, such as entrapment,11 leading
to emergency cardiac surgery or death. Our study investigated the
outcomes of the two currently available EPDs in the US: Spider FX
and Filterwire EZ. The Spider FX consists of a nitinol mesh filter with
pore sizes ranging from 70 to 200 μm with a distal floppy tip. It can be
advanced after wiring the target lesion using any guidewire according
to the operator's preference. The Filterwire-EZ is a steerable
guidewire that is advanced across the target lesion, with a 110 μm
pore size filter bag. For most sizes, both filters have similar crossing
profiles (3.2 French).
In our analysis, the most common mode of EPD failure was failure
to retrieve the filter, occurring in half of the reports. In >70% of the
cases, the filter was trapped against stent struts. While not specified
in the reviewed reports, buddy wires should never be used with EPDs,
as inadvertent stent deployment over the buddy wire will lead to filter
entrapment. To avoid filter entrapment, it is essential to avoid move-
ment of the filter wire during and after stent deployment in addition
to respecting the “landing zone” of each filter (> 40 mm for Spider
and 25–35 mm for the Filterwire-EZ). When encountering difficulty in
advancing the retrieval sheath through recently deployed stent, force-
ful advancement should be avoided, as it may result in filter move-
ment and entrapment within the recently deployed stent. Instead, the
stent may be post-dilated, and another retrieval catheter (such as the
bend tip retrieval catheter) or a guide catheter extension may be used
to remove the filter.
The second most common EPD failure mode was filter fracture
(28%), which was noted in 18 (54%) of Spider-Fx reports and 25 (29%)
of Filterwire EZ reports. Careful manipulation of the wire and filter
avoiding excessive pulling are vital to avoid this complication. Cathe-
ter-based retrieval of the filter was successful in 57% of cases but
with a lower incidence with the Spider-FX. In some cases, additional
techniques were used, including rotational atherectomy or snaring.
The device was left in place in 39% of cases. Surgical intervention was
required in 10.9% of cases. EPD failure was associated with a low risk
of death or stroke (<2%), vessel perforation or dissection (<5%), and
slow or no-reflow (<15%).
Although prior studies have shown that routine use of EPDs in
STEMIs of native coronary arteries does not improve outcomes,13
EPDs were used in native vessel PCI in 13% of the reports. In
our analysis, there was a significantly higher risk of failure to recapture
the EPD in native vessel PCI (14.3 vs. 1.1%, p < .001). It might be rea-
sonable to use EPDs in selective cases of native vessel PCI during
STEMI with massive thrombus burden and anticipation of no-reflow.
However, caution should be employed before their use, given slightly
higher risk of recapture failure.
3.1 | Limitations
Our study is limited by selection bias resulting from the retrospective
analysis of the MAUDE and the selective optional reporting by
healthcare professionals. Second, the MAUDE database has several
shortcomings, including the submission of incomplete or unverified
reports. Third, the incidence of each device's mode of failure cannot
be determined as the study lacks a denominator. Finally, a correlation
between the device failure and clinical adverse events cannot be
accurately determined.
3.2 | Conclusions
The most common modes of failure of coronary EPDs are failure of
retrieval (49.6%) and filter fracture (28.6%). When using EPDs, careful
attention to the technique is essential to avoid failures and subse-
quent complications.
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